Elizabeth M Winter1, Natasha M Appelman-Dijkstra1. 1. Department of Internal Medicine, Division of Endocrinology and Center for Bone Quality, Leiden University Medical Center, The Netherlands.
Abstract
Context: Parathyroid hormone-related protein (PTH-rP)-induced hypercalcemia or pseudophyperparathyroidism during pregnancy is a condition that can result in serious fetal and maternal complications. Among others, breast tissue might be the cause of this PTH-rP production, in which case medical treatment is possible, as we describe in this case. Setting: A 32-year-old woman presented in the 15th week of pregnancy with massive enlargement of breasts and abdominal pain due to severe hypercalcemia, hypercalciuria, and suppressed PTH. Hematological and solid malignancy were excluded. PTH-rP was found to be fourfold to eightfold increased, which is pathological even for pregnancy term. PTH-rP is produced in mammarian tissue as well as in placental tissue, in reaction to prolactin receptor activation. Prolactin hypersensitivity of breast tissue can cause excessive PTH-rP production during pregnancy. Intervention: Dopamine agonists were applied to decrease prolactin. Results: Calcium levels normalized, and PTH-rP levels became undetectable with bromocriptin treatment. A full-term healthy baby was born without disorders of calcium homeostasis, neither directly after birth nor 2 years after follow-up. After delivery, dopamine agonists could be tapered without recurrence of hypercalcemia. Conclusion: Pseudohyperparathyroidism of pregnancy was caused by increased sensitivity of mammarian tissue for prolactin, which could be treated medically, preventing emergency mastectomy.
Context:Parathyroid hormone-related protein (PTH-rP)-induced hypercalcemia or pseudophyperparathyroidism during pregnancy is a condition that can result in serious fetal and maternal complications. Among others, breast tissue might be the cause of this PTH-rP production, in which case medical treatment is possible, as we describe in this case. Setting: A 32-year-old woman presented in the 15th week of pregnancy with massive enlargement of breasts and abdominal pain due to severe hypercalcemia, hypercalciuria, and suppressed PTH. Hematological and solid malignancy were excluded. PTH-rP was found to be fourfold to eightfold increased, which is pathological even for pregnancy term. PTH-rP is produced in mammarian tissue as well as in placental tissue, in reaction to prolactin receptor activation. Prolactin hypersensitivity of breast tissue can cause excessive PTH-rP production during pregnancy. Intervention: Dopamine agonists were applied to decrease prolactin. Results:Calcium levels normalized, and PTH-rP levels became undetectable with bromocriptin treatment. A full-term healthy baby was born without disorders of calcium homeostasis, neither directly after birth nor 2 years after follow-up. After delivery, dopamine agonists could be tapered without recurrence of hypercalcemia. Conclusion: Pseudohyperparathyroidism of pregnancy was caused by increased sensitivity of mammarian tissue for prolactin, which could be treated medically, preventing emergency mastectomy.
Authors: Natasha M Appelman-Dijkstra; Diana- Alexandra Ertl; M C Zillikens; Lars Rjenmark; Elizabeth M Winter Journal: Endocrine Date: 2021-02-05 Impact factor: 3.633
Authors: Jens Bollerslev; Lars Rejnmark; Alexandra Zahn; Ansgar Heck; N M Appelman-Dijkstra; Luis Cardoso; Fadil M Hannan; Filomena Cetani; Tanja Sikjær; Anna Maria Formenti; Sigridur Björnsdottir; Camilla Schalin-Jantti; Zhanna Belaya; Fraser Wilson Gibb; Bruno Lapauw; Karin Amrein; Corinna Wicke; Corinna Grasemann; Michael Krebs; Eeva M Ryhänen; Ozer Makay; Salvatore Minisola; Sebastien Gaujoux; Jean-Philippe Bertocchio; Zaki K Hassan-Smith; Agnès Linglart; Elizabeth M Winter; Martina Kollmann; Hans-Georg Zmierczak; Elena Tsourdi; Stefan Pilz; Heide Siggelkow; Neil J Gittoes; Claudio Marcocci; Peter Kamenicky Journal: Eur J Endocrinol Date: 2022-01-13 Impact factor: 6.664
Authors: Jakub Litak; Wojciech Czyżewski; Michał Szymoniuk; Leon Sakwa; Barbara Pasierb; Joanna Litak; Zofia Hoffman; Piotr Kamieniak; Jacek Roliński Journal: Cancers (Basel) Date: 2022-09-22 Impact factor: 6.575